Most cited papers from Orlando Immunology Center

Orlando Immunology Center

What are the most cited papers from Orlando Immunology Center?

The most cited paper from Orlando Immunology Center is "Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection" (Mark Sulkowski et al., 2014), with 1,197 citations. Next come "Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV" (888) and "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study" (820).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 62 papers. Every paper with more than 100 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski et al. · New England Journal of Medicine	15 Jan 2014	1,197
2	Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV Joel E. Gallant, Edwin DeJesus, José Ramón Arribas et al. · New England Journal of Medicine	18 Jan 2006	888
3	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Eric Lawitz et al. · The Lancet	28 Jul 2014	820
4	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection Roy M. Gulick, Jacob Paul Lalezari, James Goodrich et al. · New England Journal of Medicine Open access	Oct 2008	752
5	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet	4 Aug 2009	625
6	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials Paul Edward Sax et al. · The Lancet	17 Apr 2015	601
7	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine Scott M. Hammer et al. · New England Journal of Medicine Open access	7 Oct 2013	597
8	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study Bonaventura Clotet, Judith Feinberg, Jan van Lunzen et al. · The Lancet	31 Mar 2014	509
9	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Paul Edward Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet	Jun 2012	446
10	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial Kenneth Hugh Mayer et al. · The Lancet Open access	Jul 2020	437
11	Acetabular Fracture Fixation Via a Modified Stoppa Limited Intrapelvic Approach Description of Operative Technique and Preliminary Treatment Results J. Dean Cole, Brett R. Bolhofner · Clinical Orthopaedics and Related Research	Aug 1994	426
12	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 David L. Wyles et al. · New England Journal of Medicine Open access	21 Jul 2015	425
13	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Paul Edward Sax, Anton Louis Pozniak, Marisa Montes et al. · The Lancet	Sep 2017	406
14	Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 Roberto Lozano Ortiz, Edwin DeJesus, Homayoon Khanlou et al. · AIDS	31 Jul 2008	386
15	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial Edwin DeJesus, Jürgen Kurt Rockstroh, Keith Henry et al. · The Lancet Open access	Jun 2012	347
16	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Joseph J. Eron, Patrick Yéni, Joseph Gathe et al. · The Lancet	Aug 2006	344
17	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Eric Lawitz et al. · The Lancet Infectious Diseases	15 Mar 2013	331
18	Disparities in Physical Activity and Sedentary Behaviors Among US Children and Adolescents: Prevalence, Correlates, and Intervention Implications Melicia C. Whitt‐Glover, Wendell C. Taylor, Myron F. Floyd et al. · Journal of Public Health Policy	2009	330
19	Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink et al. · New England Journal of Medicine Open access	11 May 2022	329
20	Malunited Forearm Fractures in Children Charles T. Price, Donald S. Scott, Mitchell E. Kurzner et al. · Journal of Pediatric Orthopaedics	Nov 1990	320
21	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials Joseph J. Eron et al. · The Lancet	2010	317
22	Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults Peter Jerome Ruane, Edwin DeJesus, Daniel Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	18 Apr 2013	309
23	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study Anthony Mills et al. · The Lancet Infectious Diseases	4 Nov 2015	306
24	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial Mark Sulkowski et al. · The Lancet	11 Nov 2014	280
25	Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients Edwin DeJesus, Daniel Berger, Martin H. Markowitz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	25 Aug 2006	270
26	Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection David A. Cooper et al. · The Journal of Infectious Diseases	19 Feb 2010	267
27	Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients José Ramón Arribas, Anton Louis Pozniak, Joel E. Gallant et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	2008	235
28	Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients Anton Louis Pozniak, Joel E. Gallant, Edwin DeJesus et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	18 Oct 2006	232
29	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access	17 Apr 2010	228
30	Outcome After Fixation of Unstable Posterior Pelvic Ring Injuries J. Dean Cole, David A. Blum, Lori J. Ansel · Clinical Orthopaedics and Related Research	Aug 1996	226
31	Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults Sherene Min, Louis M. Sloan, Edwin DeJesus et al. · AIDS	30 Jun 2011	221
32	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients Jürgen Kurt Rockstroh, Edwin DeJesus, Jeffrey L. Lennox et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access	14 Feb 2013	213
33	Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy Paul Edward Sax, Andrew R. Zolopa, Indira Brar et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	28 May 2014	207
34	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection Michael Kozal, Judith A. Aberg, Gilles Pialoux et al. · New England Journal of Medicine Open access	25 Mar 2020	184
35	Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial Eric S. Daar, Edwin DeJesus, Peter Jerome Ruane et al. · The Lancet HIV	18 Jun 2018	182
36	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) Eric Lawitz, Gary Matusow, Edwin DeJesus et al. · Hepatology Open access	24 Dec 2015	180
37	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial Joel E. Gallant, Eric S. Daar, François Raffi et al. · The Lancet HIV	14 Mar 2016	166
38	Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK Jürgen Kurt Rockstroh, Jeffrey L. Lennox, Edwin DeJesus et al. · Clinical Infectious Diseases Open access	16 Sep 2011	165
39	Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV ‐1‐infected treatment‐naïve patients in the ARTEMIS trial Chloe M. Orkin, E DeJesus, Homayoon Khanlou et al. · HIV Medicine Open access	23 Oct 2012	159
40	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina et al. · The Lancet HIV 140 authors	25 Mar 2018	150
41	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial Boris Dominik Jülg et al. · Nature Medicine Open access	12 May 2022	146
42	Differences in Physical Activity Prevalence and Trends From 3 U.S. Surveillance Systems: NHIS, NHANES, and BRFSS Susan A. Carlson, Dianna Densmore, Janet Elizabeth Fulton et al. · Journal of Physical Activity and Health	2009	146
43	A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection Andrew R. Zolopa, Paul Edward Sax, Edwin DeJesus et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	8 Feb 2013	146
44	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials Chloe M. Orkin et al. · The Lancet HIV Open access	Jun 2020	144
45	Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study David Phillip Serota, Eli Samuel Rosenberg, Patrick S. Sullivan et al. · Clinical Infectious Diseases Open access	6 Sep 2019	144
46	Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing George Melikian, Soo‐Yon Rhee, Vici Varghese et al. · Journal of Antimicrobial Chemotherapy Open access	9 Aug 2013	135
47	Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	21 May 2009	135
48	Randomized Controlled Trial Comparing All‐Inside Anterior Cruciate Ligament Reconstruction Technique With Anterior Cruciate Ligament Reconstruction With a Full Tibial Tunnel James H. Lubowitz, Randy Schwartzberg, Patrick A. Smith · Arthroscopy The Journal of Arthroscopic and Related Surgery	26 Jun 2013	134
49	Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution Araks Martirosyan, Rizwan Ahmad Ansari, Francisco Pestana et al. · Molecular Neurodegeneration Open access	20 Jan 2024	127
50	A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection Jürgen Kurt Rockstroh, Edwin DeJesus, Keith Henry et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	19 Jan 2013	125

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.